Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 8/20 | 0.54 |
| ▸ | HTR2C | P28335 | 9/20 | 0.39 |
| ▸ | HTR2B | P41595 | 8/20 | 0.39 |
| ▸ | HTR2A | P28223 | 6/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050934 | 0.88 | KRAS (0.61) | KRASHTR2CHTR2BHTR2ANTRK1 | |
| SCHEMBL21050781 | 0.88 | KRAS (0.59) | KRASHTR2CHTR2BHTR2ANTRK1 | |
| SCHEMBL21050919 | 0.86 | KRAS (0.72) | KRASHTR2CHTR2BHTR2ANTRK1 | |
| SCHEMBL21050647 | 0.86 | KRAS (0.72) | KRASHTR2CHTR2BHTR2ANTRK1 | |
| SCHEMBL21050835 | 0.86 | KRAS (0.49) | KRASHTR2CHTR2BHTR2ANTRK1 | |
| SCHEMBL21050666 | 0.85 | KRAS (0.65) | KRAS | |
| SCHEMBL21050641 | 0.83 | KRAS (0.77) | KRAS | |
| SCHEMBL21050705 | 0.82 | KRAS (0.62) | KRASHTR2CHTR2BHTR2A | |
| SCHEMBL21099386 | 0.82 | KRAS (0.60) | KRAS | |
| SCHEMBL21050771 | 0.80 | KRAS (0.64) | KRASHTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KRAS 272/4885HTR2C 1908/4885HTR2B 2556/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | KRAS 272/4885HTR2C 1908/4885HTR2B 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.